Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic

Although genomic classifiers have provided unprecedented insights into the biology of large B-cell lymphoma (LBCL), their ability to consistently predict outcomes across diverse patient populations and therapeutic contexts remains limited. Increasing evidence suggests that integrated models incorporating tumor genetics, transcriptional state, microenvironmental programs, and ancestry-informed biology will be required to realize the full promise of precision medicine in LBCL.